HC Wainwright & Co. Initiates Coverage On Oyster Point Pharma with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Oyster Point Pharma (NASDAQ:OYST) with a Buy rating and announces Price Target of $20.
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Oyster Point Outlines Restructuring Plan With Savings Of Up To $48M In 2023
Oyster Point Pharma Inc (NASDAQ:OYST) will implement an operating expense streamlining plan to reduce employee and non-employee expenses (up to 50…
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Earnings Preview: Oyster Point Pharma
Oyster Point Pharma (NASDAQ:OYST) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Oyster Point Pharma will report an earnings per share (EPS) of $-1.74.
Oyster Point Pharma Wins $32.9M Contract From Office Of Veterans Affairs
https://sam.gov/opp/3c9d743cf21d452b98fa9011caa4b755/view
